Oculis Holding

OCS Rare disease Lead: Phase 3 ★ Read the deep dive → 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-04

Catalyst timeline

Privosegtor IND filing2H 2026Privosegtor IND filing, 2H 2026, notable
Licaminlimab pivotal topline4Q 2026/1Q 2027Licaminlimab pivotal topline, 4Q 2026/1Q 2027, thesis-defining
Privosegtor pivotal readout2027Privosegtor pivotal readout, 2027, material
ACT-02 corporate updateMar 31, 2027ACT-02 corporate update, Mar 31, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Licaminlimab

OCS-02

Protein Target: TNFα

Dry Eye Disease Phase 2 Phase 2/3 trial topical Novartis NCT05896670

Privosegtor

OCS-05 · ACT-01

Small Molecule

Optic Neuritis Phase 3 Accure Therapeutics NCT04762017
Non-Arteritic Anterior Ischemic Optic Neuropathy Accure Therapeutics
Multiple Sclerosis Preclinical Accure Therapeutics

Technology platforms

OPTIREACH

Proprietary cyclodextrin-based solubilizing formulation technology that improves solubility of lipophilic drugs, increases residence time on the eye surface, and enables topical delivery of therapeutics to the posterior segment of the eye; focus area: ophthalmic diseases including DME

Discontinued (1)

OCS-01 — Diabetic Macular Edema · company does not plan to pursue FDA regulatory filing following DIAMOND topline results

Biotech Distilled coverage (4)

2026-08-11 UPDATE: Oculis Holding AG (OCS) - They Bought the Farm 🔒 Paid
2026-08-07 UPDATE: Oculis Holding AG (OCS) - The Clock on PREDICT-1 Is Now Readable 🔒 Paid
2026-08-04 UPDATE: Oculis Holding AG (OCS) - The Neuroprotectant Gets a Bigger Door 🔒 Paid
2026-06-05 Oculis Holding AG (OCS) — Scientific Deep Dive for Privosegtor, Licaminlimab, and the OCS-01 Wreckage

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.